Last checked at 
LONDON (Alliance News) - Pharmaceutical company Shield Therapeutics PLC said Thursday it has had positive top-line results from its paediatric phase I pharmacokinetics study of its ferric iron therapy, Feraccru.
Feraccru is the company's oral dose of non-salt ferric iron which does not cause the same treatment-limiting issues as salt-based oral iron such as nausea, bloating and constipation.
The study, conducted on 36 subjects between 12 and 17 years old, achieved all the pre-defined goals of the protocol. It also demonstrated positive effects on serum iron parameters over the duration of the study and showed good tolerance at all dosing levels.
"Positive results from the study should lead to Feraccru being granted a paediatric license, thus providing an even larger commercial opportunity for this effective therapy in the treatment of iron deficiency," the company said.
Shield shares were trading up 1.3% at 40.50 pence each.
